Myriad Genetics (MYGN) to Release Earnings on Tuesday

Share on StockTwits

Myriad Genetics (NASDAQ:MYGN) will release its earnings data after the market closes on Tuesday, August 14th. Analysts expect Myriad Genetics to post earnings of $0.33 per share for the quarter.

Myriad Genetics opened at $42.53 on Monday, Marketbeat Ratings reports. The company has a market cap of $3.05 billion, a PE ratio of 40.50, a P/E/G ratio of 2.90 and a beta of 0.49. Myriad Genetics has a 52 week low of $27.22 and a 52 week high of $44.87. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.52 and a quick ratio of 3.16.

Several research firms have recently commented on MYGN. ValuEngine raised Myriad Genetics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 24th. Bank of America upped their target price on Myriad Genetics from $20.00 to $31.00 and gave the company an “underperform” rating in a report on Monday, July 16th. Morgan Stanley raised Myriad Genetics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $35.00 to $55.00 in a report on Wednesday, July 11th. TheStreet raised Myriad Genetics from a “c+” rating to a “b” rating in a report on Monday, June 4th. Finally, Zacks Investment Research lowered Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 18th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $36.40.

In other news, Director Dennis Langer sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, May 21st. The stock was sold at an average price of $35.90, for a total transaction of $359,000.00. Following the completion of the transaction, the director now directly owns 49,743 shares in the company, valued at $1,785,773.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jerry S. Lanchbury sold 60,000 shares of the business’s stock in a transaction that occurred on Monday, June 18th. The stock was sold at an average price of $40.12, for a total value of $2,407,200.00. Following the transaction, the insider now owns 196,463 shares of the company’s stock, valued at $7,882,095.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 506,811 shares of company stock valued at $20,256,716. Insiders own 6.70% of the company’s stock.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Further Reading: Price to Earnings Ratio (PE) Basics

Earnings History for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply